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ABSTRACT Childhood immunization programs may pro-
vide infrastructure for delivering vitamin A supplements to
infants in developing countries. The effect of giving vitamin
A, an immune enhancer, on antibody responses to trivalent
oral poliovirus vaccine (TOPV) is unknown. A randomized,
double-blind, placebo-controlled clinical trial was con-
ducted to determine the effect of giving vitamin A simulta-
neously with TOPV on antibody responses to poliovirus.
Infants (n 5 467) received oral vitamin A, 15 mg retinol
equivalent (RE), 7.5 mg RE or placebo with TOPV at 6, 10
and 14 wk of age. Antibody responses to poliovirus types 1,
2 and 3 were measured by a microvirus neutralization assay
at enrollment and at 9 mo of age. Seroconversion rates to
poliovirus types 1, 2 and 3 ranged from 98 to 100% in the
three treatment groups, and there were no differences in
mean antibody titers to poliovirus types 1, 2 and 3 among
treatment groups. This study demonstrates that oral vita-
min A does not affect antibody responses to poliovirus
vaccine when integrated with the Expanded Program on
Immunization. J. Nutr. 129: 2203–2205, 1999.
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Vitamin A deficiency is a major cause of childhood mor-
bidity and mortality in developing countries (Sommer and
West 1996). Periodic high dose vitamin A supplementation
has been shown to reduce child mortality by about one third
(Beaton et al. 1993). The infrastructure of childhood immu-
nization programs involves an estimated 500 million child
contacts per year; it has been suggested that this infrastructure
could be used for the delivery of micronutrient supplements to
infants [Expanded Program on Immunization (EPI)3 Global
Advisory Group 1987]. Vitamin A, through its active metab-
olites, controls the transcriptional activation of many genes, is
a potent modulator of many different pathways in the immune
system and is known to influence responses to vaccination
(Semba 1998). Oral high dose vitamin A given simultaneously
with standard titer Schwarz measles vaccine may interfere with
seroconversion to the measles virus in 6-mo-old infants who
have high levels of maternal antibody to measles virus (Semba
et al.1995), but not in 9-mo-old infants who have low levels or
no maternal antibody to measles virus (Benn et al. 1997,
Semba et al. 1997). Trivalent oral poliovirus vaccine (TOPV)
is also a live attenuated vaccine, and there is concern that oral
vitamin A could interfere with seroconversion to TOPV when
given simultaneously in childhood immunization programs.
We conducted a randomized, double-blind, placebo-controlled
clinical trial to determine the effect of simultaneous vitamin A
administration on antibody responses to TOPV in infants.
SUBJECTS AND METHODS
The study population consisted of infants in 27 villages in Bogor
District, West Java, Indonesia, an area with a high prevalence of sub-
clinical vitamin A deficiency (Semba 1995). After written, informed
consent was obtained from the mother or father, infants were enrolled in
the clinical trial between October 1992 and February 1993. Details of
this clinical trial have been described elsewhere (Semba et al. 1997).
Infants were randomly allocated by number table in blocks of 10 to
receive 15 mg retinol equivalent (RE), 7.5 mg RE of vitamin A or
placebo at 6, 10 and 14 wk of age. At age 6, 10 and 14 wk, infants
received TOPV [Polioral, Biocine Sclavo, Siena, Italy, lot 73A12, 1.15
mL volume, tissue culture dose 50% infectivity (TCID50) for type 1, 2
and 3: 106.0, 105.0, and 105.8, respectively] and diphtheria-pertussis-
tetanus vaccine (Biofarma, Bandung, Indonesia) administered by a pe-
diatrician. Vitamin A and placebo solutions were dispensed from amber
glass micronutrient dispensers (Swift dispensers, Englass, Leicester, U.K.)
within 10–30 min after TOPV immunization. TOPV was not adminis-
tered to the infants at birth. The cold chain was extensively monitored
during shipping from the factory in Siena, Italy to the study laboratory in
Bogor, Indonesia using temperature-sensitive monitors. All infants were
seen and examined by a pediatrician at each visit. At the time of
treatment allocation, both the pediatrician and study nurse were required
to verify the identification number of the infant. Height, weight, mid
upper-arm circumference and head circumference were measured by a
well-trained anthropometrist when the infants were 6 and 14 wk of age.
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Blood was obtained by venipuncture at 6 and 14 wk, and 9 mo of
age, and plasma was separated and frozen at 270°C. Plasma vitamin
A levels were measured by HPLC at 6 and 14 wk (Semba et al. 1997).
Antibody titers to poliovirus serotypes were measured by a microvirus
neutralization assay (Kapsenberg et al. 1981) and were standardized
against poliovirus reference sera (World Health Organization, Ge-
neva, Switerland). Seroconversion to poliovirus was defined as a
positive antibody titer at 9 mo of age ($2), minus the calculated
expected titer of passively acquired maternal antibody to poliovirus,
assuming a half-life of immunoglobulin G to be 4 wk. The virus
neutralizing antibody level considered to be consistent with protec-
tion against poliovirus at 9 mo of age was $8 (WHO Expert Com-
mittee on Biological Standardization 1988). Categorical analyses
were conducted using x-square and exact tests. Student’s and Bon-
ferroni’s t tests were used for appropriate comparisons of continuous
data. A paired t test was used to compare plasma vitamin A levels at
baseline and follow-up. The study protocol was approved by the
ethical review committees at the Johns Hopkins School of Medicine,
the Ministry of Health, Government of Indonesia, and the WHO
Secretariat Committee on Research Involving Human Subjects.
RESULTS
There were 467 infants enrolled in the study at age 6 wk.
Follow-up rates of the infants to 10 and 14 wk and 9 mo were
93.6, 91.6 and 84.5%, respectively. Characteristics of infants
in the three treatment groups are shown in Table 1. There
were no significant differences in weight, height or other
anthropometric measurements at baseline. Antibody titers to
poliovirus were measured in 353 of 394 infants who were seen
both at enrollment and at 9 mo of age. Plasma samples were
unavailable for 41 infants because of insufficient sample vol-
ume. Seroconversion rates to the three poliovirus types by
treatment group are shown in Table 2. The rates of serocon-
version were 97–100%, with no significant differences among
treatment groups in seroconversion to any of the three polio-
virus types. The proportion of infants with titers $8, a level
considered to confer protection against poliovirus, is shown in
Table 2. The proportion of infants with protective titers
against the three respective polioviruses ranged from 93.1 to
99.1%, with no significant differences in protection among
treatment groups. Loge antibody titers to the three poliovirus
types did not differ by treatment group (Table 3). There were
no significant differences in geometric mean titers to any of
the poliovirus types among treatment groups. There were no
cases of polio among the infants in the study during follow-up.
DISCUSSION
This study shows that vitamin A supplementation given
concurrently with TOPV immunization at the 6-, 10- and
14-wk visits of the Expanded Program on Immunization does
TABLE 1
Characteristics of mothers and infants in Indonesia by allocation group
Characteristic1,2
Placebo
(n 5 156)
Vitamin A 7.5 mg RE
(n 5 156)
Vitamin A 15 mg RE
(n 5 155)
Maternal age, y 26.5 6 0.5 26.2 6 0.5 26.0 6 0.5
Infant age, d 53.8 6 0.8 53.1 6 0.8 52.7 6 0.9
Infant gender 82 M, 74 F 88 M, 68 F 86 M, 69 F
Weight, kg 4.75 6 0.06 4.65 6 0.05 4.74 6 0.05
Height, cm 55.8 6 0.2 55.8 6 0.2 55.9 6 0.2
Mid upper-arm circumference, cm 12.55 6 0.08 12.35 6 0.09 12.56 6 0.09
Head circumference, cm 37.7 6 0.1 37.5 6 0.1 37.7 6 0.2
Plasma retinol, baseline, mmol/L 0.61 6 0.01 0.61 6 0.01 0.61 6 0.01
Plasma retinol, 14 wk, mmol/L 0.64 6 0.01 0.73 6 0.023 0.76 6 0.023
Plasma retinol ,0.35 mmol/L at baseline, % 10.97 11.04 10.97
Plasma retinol ,0.35 mmol/L at 14 wk, % 7.19 1.40 1.384
1 No significant difference was noted among groups for all characteristics shown, except for plasma retinol at 14 wk. Plasma retinol was measured
in 139, 143, and 145 subjects of placebo, 7.5 mg retinol equivalent (RE), and 15 mg RE vitamin A groups at 14 wk, respectively.
2 For continuous variables, mean 6 SEM.
3 Paired t test, difference in plasma retinol between baseline and 14 wk, P , 0.0001.
4 Vitamin A–supplemented groups different from placebo by Mantel-Haenszel x-square, P , 0.006.
TABLE 2
Seroconversion rates and protection against poliovirus types 1, 2, 3 in Indonesian infants
Poliovirus Placebo
Vitamin A
(25,000 IU)
Vitamin A
(50,000 IU) P-value
Seroconversion1
Type 1 91/92 (98.9%) 109/110 (99.1%) 100/102 (98.0%) 0.77
Type 2 113/113 (100%) 124/124 (100%) 116/116 (100%) 1.00
Type 3 111/112 (99.1%) 122/122 (100%) 113/113 (100%) 0.99
Protection2
Type 1 87/92 (94.5%) 104/110 (94.5%) 95/102 (93.1%) 0.88
Type 2 112/113 (99.1%) 122/124 (98.4%) 114/116 (98.3%) 0.84
Type 3 108/113 (95.6%) 121/123 (98.3%) 111/115 (96.5%) 0.45
1 Detectable neutralizing antibody titer at 9 mo of age, adjusting for half-life of maternal antibody titer at enrollment.
2 Antibody titer $8 at follow-up visit at 9 mo of age (World Health Organization Expert Committee on Biological Standardization 1988).
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not interfere with seroconversion to any of the three polio
types. In addition, there were no significant differences among
the three treatment groups in the proportion of infants who
had antibody titers considered protective against polio and in
the mean antibody titers against the three polio types. In a
different but related study design, vitamin A supplementation
to mothers but not their infants did not interfere with sero-
conversion to oral poliovirus vaccine (Bhaskaram and Bal-
akrishna 1998). Vitamin A supplementation given at the time
of measles immunization has been shown to interfere with
antibody responses to measles in infants with high levels of
maternal antibody, but not in infants with little to no mater-
nal antibody to measles (Benn et al. 1997, Semba et al. 1995
and 1997). The mode of delivery of vaccine (oral vs. subcu-
taneous) and type of virus may account for some of the
differences between possible effects of vitamin A on immune
responses to vaccination.
Although TOPV is generally considered effective, this
study shows that it is possible to have higher rates of serocon-
version and protection than those generally reported from
developing countries using TOPV (Patriarca et al. 1991).
Factors that might affect the efficacy of TOPV include the
vaccine potency, vaccine stability, age at first dose, the inter-
val between doses and dosage volume. The TOPV used in this
study met the requirements for potency developed by the
Expert Committee on Biologic Standardization (WHO Expert
Committee 1988), and the cold chain was strictly monitored
from the factory until the moment it was administered in the
clinic. The age at first dose and interval between doses fol-
lowed the guidelines of the EPI. This study suggests that strict
adherence to WHO guidelines for potency and administration
of TOPV can result in high rates of seroconversion and pro-
tection from polio in a developing country such as Indonesia.
Infancy is a high risk period for the development of micro-
nutrient deficiencies in many developing world populations,
and the integration of vitamin A supplementation with the
EPI, in addition to periodic high dose vitamin A supplemen-
tation for preschool children, is proceeding in some countries
in which vitamin A deficiency is a public health problem.
Integration of vitamin A supplementation with the EPI im-
proves vitamin A status of infants but seems to have no effect
on infant morbidity and mortality (WHO/CHD Immunisa-
tion-Linked Vitamin A Supplementation Study Group 1998).
The infrastructure of the EPI also offers the opportunity to
supplement infants with oral iodized oil. In Indonesia, infants
receiving oral iodized oil capsules given through the EPI at 6
wk of age had lower mortality rates, presumably because of an
effect of oral iodized oil on thyroid status and immunity
(Cobra et al. 1997). In the same trial, oral iodized oil did not
interfere with seroconversion to TOPV when given through
the EPI (Taffs et al. 1999).
This study suggests that oral vitamin A supplementation
can be integrated with the EPI without an adverse effect on
antibody responses to oral poliovirus vaccine and that high
seroconversion rates can be achieved with careful monitoring
of the cold chain. Integration of vitamin A with the EPI
should be considered in countries in which clinical and sub-
clinical vitamin A deficiency is endemic.
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TABLE 3
Loge antibody titers against poliovirus types 1, 2, 3
in 9-mo-old Indonesian infants1,2
Poliovirus Placebo
Vitamin A 7.5 mg
RE
Vitamin A 15 mg
RE
Type 1 5.26 6 0.16 [92] 5.63 6 0.16[110] 5.32 6 0.17[102]
Type 2 5.95 6 0.12[113] 6.02 6 0.12[124] 5.96 6 0.11[116]
Type 3 5.36 6 0.14[113] 5.44 6 0.12[123] 5.21 6 0.12[115]
1 No significant differences noted between allocation groups.
2 n in each group in brackets.
RE, retinol equivalent.
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